High accuracy variant calling with detailed reporting on mutations found in each sample.
Patients are matched with trials that are seeking specific molecular profiles.
Reporting on Micro-satellite instability (MSI) and tumor mutational burden (TMB)*.
Chosen from a range of molecularly targeted FDA-approved, off label, or experimental therapies.
*Some features are currently in development and are due to be added soon.